

#41  
Suppl.  
ResponseAtty. Dkt. No. EPI3007B  
(formerly TSRI 184.2C2)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Hein et al.


Title: TRANSGENIC PLANTS EXPRESSING  
ASSEMBLED SECRETORY  
ANTIBODIES

Appl. No.: 09/200,657

Filing Date: 11/25/98

Examiner: Collins, Cynthia E

Art Unit: 1638

<b>CERTIFICATE OF FACSIMILE TRANSMISSION</b>	
I hereby certify that this paper is being facsimile transmitted to the United States Patent & Trademark Office, Washington, D.C. on the date below.	
	<u>Germaine Sarda</u> (Printed Name)
	(Signature)
<u>May 30, 2003</u> (Date of Deposit)	

**SUPPLEMENTAL COMMUNICATION**Mail Stop NON-FEE AMENDMENT  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

This supplemental communication concerning the above-captioned application follows an amendment filed April 2, 2003, responsive to the Office Action dated January 2, 2003.

**REJECTION OF CLAIMS 81-83, 88-90 and 93-94**  
**UNDER 35 U.S.C. § 102 OVER GOODMAN**

Further included with Applicant's arguments from April 2, 2003 obviating the rejection is the file history of the Goodman patent, which evidences the position of the Patent Office that Goodman does not enable plant expression of any non-plant polypeptide other than interferon.

The Goodman patent issued from U.S. application serial no. 760,236 filed July 29, 1985. Claim 1 of 760,236 broadly drawn to a "method for producing a mammalian peptide" is limited to expressing a single mammalian polypeptide. Original claims of 760,236 are attached as EXHIBIT 1. Thus, the originally filed claims indicate that